Abstract
Indirubin is an active ingredient mainly used to treat leukemia in China and is reported to be a leading inhibitor of cyclindependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) by competing with ATP binding sites. New findings have indicated that its comprehensive structure may contribute to its polypharmacological activities particularly in cancer and neurodegenerative disease therapy, as both of these diseases are usually accompanied by a common molecular link related to abnormal phosphorylation of CDKs and GSK-3. In the elderly, cancer and neurodegenerative disease are tightly associated common diseases and sometimes unavoidably coexist. In this review, the underlying mechanisms of the dual actions of indirubin and its structurally-related compounds in cancer and neurodegenerative disease therapy are presented.
Keywords: cancer, CDKs, dual function, GSK-3, indirubin, neurodegeneration.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Volume: 14 Issue: 9
Author(s): Ying Wang, Pui Man Hoi, Judy Yuet-Wa Chan and Simon M.-Y. Lee
Affiliation:
Keywords: cancer, CDKs, dual function, GSK-3, indirubin, neurodegeneration.
Abstract: Indirubin is an active ingredient mainly used to treat leukemia in China and is reported to be a leading inhibitor of cyclindependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) by competing with ATP binding sites. New findings have indicated that its comprehensive structure may contribute to its polypharmacological activities particularly in cancer and neurodegenerative disease therapy, as both of these diseases are usually accompanied by a common molecular link related to abnormal phosphorylation of CDKs and GSK-3. In the elderly, cancer and neurodegenerative disease are tightly associated common diseases and sometimes unavoidably coexist. In this review, the underlying mechanisms of the dual actions of indirubin and its structurally-related compounds in cancer and neurodegenerative disease therapy are presented.
Export Options
About this article
Cite this article as:
Wang Ying, Hoi Man Pui, Chan Yuet-Wa Judy and Lee M.-Y. Simon, New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (9) . https://dx.doi.org/10.2174/1871520614666140825112924
DOI https://dx.doi.org/10.2174/1871520614666140825112924 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect
Current Pharmaceutical Biotechnology Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry Biological Interfacial Engineering for Metastatic Cancer Diagnosis and Intervention
Current Medicinal Chemistry Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science RGD Peptide–mediated Molecular Imaging for Targeting Integrin Alpha(v) Beta(3) in Tumors: A Review
Current Medical Imaging In vivo Near-infrared Fluorescence Tumor Imaging Using DiR-loaded Nanocarriers
Current Drug Delivery Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets Short Commentary on “Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis, and Therapy”
Current Medicinal Chemistry CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry Mesenchymal Stem Cells for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
Current Pharmaceutical Design LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry